Figure 7

Downmodulation of NKG2D, NKp46, and NKp30 in NK-92 cells co-cultured with Cervical cancer cell (CCC) lines. CCC were pre-treated with the Heme oxygenase 1 (HO-1) inhibitor (SnPP) for 48 h; after that, NK-92 cells were co-cultured with HeLa, SiHa, and C-33A CCC for 4 h. Then, the expression of NKp30, NKp44, NKp46, and NKG2D was analyzed in NK-92 cells by Flow cytometry (FC). Expression of NKp30, NKp44, NKp46, and NKG2D in NK-92 (Basal group) (a). Expression of NKp30, NKp44, NKp46, and NKG2D in NK92/HeLa cell co-culture (b). Expression of NKp30, NKp44, NKp46, and NKG2D in NK92/SiHa cell co-cultures (c). Expression of NKp30, NKp44, NKp46, and NKG2D in NK92/C-33A cell co-cultures (d). Bars represent the mean ± Standard deviation (SD). Results are represented as the mean ± Standard deviation (SD) of three independent experiments performed in triplicate. *P <0.05 1:5 + SnPP or 1:20 + SnPP vs. 1:5 or 1:20 in NKG2D, NKp46, and NKP30 in HeLa, SiHa, or C-33A. Mann-Whitney U test.